TREX1 gene polymorphisms: To assess the prevalence of selected autoantibodies as (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB) and TREX1 gene polymorphisms in SLE patients, and their association with clinical features and disease activity
Study summary
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Adult aged 18-60 years
* Diagnosed as SLE per 2019 EULAR/ACR classification criteria.
* Presence of at least one cutaneous manifestation (acute, subacute, or chronic).
* Willing to provide written informed consent for participation and genetic testing
Exclusion Criteria:
* Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis).
* Systemic infection, malignancy, or pregnancy.
* Use of biologic therapy or immunosuppressive pulses within one month.
Primary outcome measure(s)
Systemic Lupus Erythematosus Assessment — 3 Months Assessment of disease activity in Systemic Lupus Erythematosus (SLE) using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). SLEDAI-2K as follows :
1-5 is Mild disease activity 6-10 is Moderate disease activity 11 or more is Severe disease activity
TREX1 gene polymorphism and SLE — 3 Months Assessment the association between TREX1 gene polymorphism and systemic lupus erythematosus susceptibility
Trial sites (1)
Facility
City
Region
Status
Qina University hospital, South Valley University Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.